Drug intelligence / Profile preview

CD83-positive mesenchymal stem cells

Development stage
Phase 1
Lead developer
PLA Army Specialty Medical Center
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

CD83-positive mesenchymal stem cells are a specialized subpopulation of mesenchymal stem cells (MSCs) characterized by the expression of the CD83 surface marker. These cells are being investigated as a cell-based therapy, primarily for their immunomodulatory and regenerative properties. MSCs generally exert their therapeutic effects through direct cell-to-cell contact with various immune cells and the secretion of soluble factors, including cytokines, chemokines, and growth factors, which collectively suppress inflammation and promote tissue repair. The presence of CD83 on these MSCs is believed to enhance their immune-regulatory functions, potentially by influencing the maturation and function of other immune cells like dendritic cells. They are currently being explored for their potential in treating severe inflammatory conditions such as sepsis.

Other names
CD83+MSCs

Beyond the preview

Go deeper on CD83-positive mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD83-positive mesenchymal stem cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call